Table 2

Biopathological characteristics
Total (pT1a and pT1b) pT1a pT1b
N. of patients 402 82 320
Histology
Ductal 336 (83.6%) 70 (85.4%) 266 (83.1%)
Lobular 38 (9.5%) 7 (8.5%) 31 (9.7%)
Mixed 5 (1.2%) 0 (0.0%) 5 (1.6%)
Other 23 (5.7%) 5 (6.1%) 18 (5.6%)
Vascular invasion
Yes 30 (7.5%) 3 (3.7%) 27 (8.4%)
No 267 (66.4%) 51 (62.2%) 216 (67.5%)
Unknown 105 (26.1%) 28 (34.1%) 77 (24.1%)
Grading
G1 101 (25.1%) 18 (22.0%) 83 (25.9%)
G2 221 (55.0%) 46 (56.1%) 175 (54.7%)
G3 72 (17.9%) 15 (18.3%) 57 (17.8%)
Unknown 8 (2.0%) 3 (3.7%) 5 (1.6%)
Proliferation index (Ki-67/MB1)
0–18% 283 (70.5%) 53 (64.6%) 230 (71.8%)
19–29% 52 (12.9%) 17 (20.7%) 35 (10.9%)
≥ 30% 54 (13.4%) 7 (8.5%) 47 (14.7%)
Unknown 13 (3.2%) 5 (6.1%) 8 (2.5%)
ER status
ER positive (≥ 10%) 351 (87.3%) 65 (80.5%) 285 (89.1%)
ER negative (0–9%) 51 (12.7%) 16 (19.5%) 35 (10.9%)
PgR status
PgR positive (≥ 10%) 300 (74.6%) 54 (65.9%) 246 (76.9%)
PgR negative (0–9%) 102 (25.4%) 28 (34.1%) 74 (23.1%)
Hormonal status*
ER and/or PgR positive 354 (88.1%) 65 (81.7%) 287 (89.7%)
ER and PgR negative 48 (11.9%) 15 (18.3%) 33 (10.3%)
HER2 status**
Positive 49 (12.2%) 19 (23.2%) 30 (9.3%)
Negative 344 (85.6%) 62 (75.6%) 282 (88.2%)
Unknown 9 (2.2%) 1 (1.2%) 8 (2.5%)
pN status
pN0 319 (79.4%) 67 (81.7%) 252 (78.8%)
pN1 (1–3) 74 (18.4%) 12 (14.6%) 62 (19.4%)
pN2 (4–9) 6 (1.5%) 2 (2.4%) 4 (1.3%)
pN3 (≥ 10) 3 (0.7%) 1 (1.2%) 2 (0.6%)

* cut off: 10%

** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH

Gori et al.

Gori et al. BMC Cancer 2012 12:158   doi:10.1186/1471-2407-12-158

Open Data